Original Article
Predictors and long-term prognosis of early and late recurrence for patients undergoing hepatic resection of hepatocellular carcinoma: a large-scale multicenter study
This large-scale multicentric study demonstrated that independent predictors associated with early and late recurrence after curative resection for patients with HCC were generally same, although several did differ. The study also showed patients with early recurrence had worse long-term survival than patients with late recurrence.
Microvascular invasion of hepatocellular carcinoma predicts microvascular invasion of its recurrence: potential implications for salvage liver transplantation?
The absence of microvascular invasion in a recurrent hepatocellular carcinoma can be predicted by the histological features of the initial tumor.
Prognostication algorithm for non-cirrhotic non-B non-C hepatocellular carcinoma—a multicenter study under the aegis of the French Association of Hepato-Biliary Surgery and liver Transplantation
This prognostication algorithm based on the number (≤ or > 2) and size ( 10cm), which could be used as a treatment decision support concerning the need for perioperative therapy. It highlighted distinctive groups of non-cirrhotic HCC patients with different prognoses.
Robotic versus laparoscopic liver resection for huge (≥10 cm) liver tumors: an international multicenter propensity-score matched cohort study of 799 cases
In a cohort of 100 robotic and 699 laparoscopic liver resections performed for huge tumors, a 1:3 propensity score matched study comparing between robotic and laparoscopic liver resections were performed. Both robotic and laparoscopic liver resections could be performed safely for huge liver tumours. There was no significant difference between the key perioperative outcomes between both groups.
Review Article
A review of 2022 Chinese clinical guidelines on the management of hepatocellular carcinoma: updates and insights
The highlight of this review is summarized as follows: This review briefly presented updated recommendations on the management of hepatocellular carcinoma in the 2022 version of Chinese guidelines. Comparisons with updates in the 2022 Barcelona Clinic Liver Cancer guidelines and Japanese Society of Hepatology consensus statement were made to discuss regional variations.
French Editorial Commentary from the ACHBPT
Editorial Commentary
Editorial
Letter to the Editor
Letter in Reply
Images in Clinical Medicine
